First comprehensive look at breast cancer in Native American women reveals key genetic differences
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 06:15 ET (22-Jun-2026 10:15 GMT/UTC)
A study by IRB Barcelona and Centro de Investigación del Cáncer in Salamanca demonstrates that eliminating mutated KRAS protein using PROTACs induces rapid tumour regression in mouse models of lung adenocarcinoma.
The work identifies resistance mechanisms distinct from those observed with classic KRAS inhibitors, a relevant finding as the first KRAS degraders are already in clinical trials.
Published in Cancer Research, the developed model could help evaluate future targeted protein degradation-based therapies against other oncoproteins.
Researchers from UC San Diego have uncovered a new possibility for treating melanoma, and it's something we have in our bodies already.
Weekly updates from NCCN share every time a change is made to evidence-based, expert consensus-driven guidelines for cancer prevention, screening, treatment, and supportive care. Learn more at NCCN.org/updates.
Cancer scientists have discovered that lung cancer cells can change their identity to resist treatment.
With colorectal cancer a growing concern among younger people, the American Cancer Society has endorsed two new types of stool tests to encourage people to get screened while also recommending a limited role for new blood tests many patients find appealing.
Artificial intelligence is rapidly changing how biomedical materials are discovered and designed. In a new review published in Science Bulletin, researchers summarize how machine learning and generative AI are helping scientists predict material behaviors such as drug release, biocompatibility, and catalytic activity, and even propose entirely new inorganic materials for biomedical applications. The review highlights emerging applications in drug delivery, cancer therapy, anti-inflammatory treatment, and tissue engineering, while also discussing the challenges that still limit clinical translation.
Androgen receptor (AR) signaling plays a critical role in prostate cancer progression and remains a primary therapeutic target. Despite the efficacy of androgen deprivation therapy (ADT), most patients eventually develop castration-resistant prostate cancer (CRPC), characterized by the reactivation of AR signaling through various mechanisms. While the role of AR as a transcriptional activator is well-documented, emerging research indicates that it also functions as a transrepressor for specific targets.